ArticlePloS one2014
Comparative in vivo analysis of recombinant type II feline coronaviruses with truncated and completed ORF3 region.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- A colloidal gold immunochromatographic test strip based on mAbs anti-N protein to detect feline coronavirus.Microbiology spectrum · 2025Article
- Development of a rapid reverse genetics system for feline coronavirus based on TAR cloning in yeast.Frontiers in microbiology · 2023Article
- Comparative sequence analysis of the accessory and nucleocapsid genes of feline coronavirus strains isolated from cats diagnosed with effusive feline infectious peritonitis.Archives of virology · 2021Article
- FCoV Viral Sequences of Systemically Infected Healthy Cats Lack Gene Mutations Previously Linked to the Development of FIP.Pathogens (Basel, Switzerland) · 2020Article
- Review
- Mutation of the S and 3c genes in genomes of feline coronaviruses.The Journal of veterinary medical science · 2018Article
- Feline Coronaviruses: Pathogenesis of Feline Infectious Peritonitis.Advances in virus research · 2016Review
- Feline Coronavirus 3c Protein: A Candidate for a Virulence Marker?BioMed research international · 2016Article
- Characterisation of different forms of the accessory gp3 canine coronavirus type I protein identified in cats.Virus research · 2015Article
- Crystallization and preliminary crystallographic study of Feline infectious peritonitis virus main protease in complex with an inhibitor.Acta crystallographica. Section F, Structural biology communications · 2014Article
- Recombinant feline coronaviruses as vaccine candidates confer protection in SPF but not in conventional cats.Veterinary microbiology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our previous in vitro comparative study on a feline coronavirus (FCoV) pair, differing only in the intactness of their ORF3abc regions, showed that the truncated ORF3abc plays an important role in the efficient macrophage/monocyte tropism of type II feline infectious peritonitis virus (FIPV). In the present study, we describe a challenge experiment with the same recombinant FCoVs in order to gain data on the in vivo characteristics on these viruses. While parent virus FIPV DF-2 developed feline infectious peritonitis in all the infected cats, its recombinant virus PBFIPV-DF-2, differing only in seven nucleotides, proved to be surprisingly low virulent, although caused an acute febrile episode similarly to the original FIPV DF-2. PBFIPV-DF-2 infection induced significantly lower virus neutralization titers than its parent virus, and lacked the second phase of viremia and development of fatal course of the disease. The recombinant PBFIPV-DF-2-R3i with completed ORF3abc gained biological properties that differentiate between the feline enteric coronavirus (FECV) and FIPV biotypes such as intensive replication in the gut, absence of viremia and weak or no serological response. Using reverse genetic approaches our study is the first experimental proof that ORF3abc is indeed responsible for the restriction of FECV replication to the intestine in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.